Developer docs
API playgroundTry for free, no card

Search company profiles

SpinDiag

Full company profile

uuid0002srv

Namestring
SpinDiag
Legal namestring
Spindiag GmbH
Websiteurl
spindiag.de
Company typeenum
Private
Founded yearint
2016
Descriptiontext

SpinDiag GmbH is a German diagnostics company headquartered in Freiburg that develops a rapid, automated, point-of-care PCR testing platform for infectious disease detection, with publicly disclosed applications including SARS-CoV-2 and other pathogens. The company's core product is a compact, easy-to-use PCR system designed to deliver laboratory-grade molecular diagnostic results outside of centralized lab settings, with speed (performance_speed) cited as the primary technical differentiator. The platform is positioned for use by healthcare providers and medical laboratories — a B2B customer segment characterized by hospital systems, clinical labs, and point-of-care clinical sites requiring rapid, accurate infectious disease diagnosis. Revenue model, pricing, and distribution channels are not publicly disclosed; the company is privately held and was founded in 2016.

SpinDiag has raised approximately $42 million across five funding rounds between 2017 and 2022, including a €15 million debt facility from the European Investment Bank in October 2022 earmarked for R&D, production scale-up, and geographic expansion across European markets. The leadership team is founder-heavy, with multiple technical co-founders (CSO, CTO, CPO, and a scientific co-founder) alongside dedicated CEO, COO, and CFO functions, reflecting an organization built for both deep product development and commercial scaling. Operating geographies are centered on Germany with broader European expansion signaled via EIB-financed commercialization.

Significant uncertainty is introduced by the fact that SpinDiag's primary web domain (spindiag.de) appears to have been repurposed for unrelated online casino and gambling content, an indicator of operational disruption, domain expiry, or business discontinuation that is not otherwise explained in the available data and which materially affects any assessment of current commercial status.

Short descriptiontext

SpinDiag (Spindiag GmbH) is a Freiburg, Germany-based diagnostics startup that develops a rapid, automated point-of-care PCR testing platform for detecting infectious disease pathogens such as SARS-CoV-2, serving healthcare providers and medical laboratories across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFreiburg, Germany
HQ citystring
Freiburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
PCR diagnostic testing, infectious disease detection, point-of-care diagnostics, molecular diagnostics platform, rapid pathogen testing
Industry1 code
1Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
CodeHLAHAOAIPrimaryYes
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles1 record
Cost components4 values
Technology or R&D, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SpinDiag (Spindiag GmbH) develops an easy-to-use, compact, and automated point-of-care rapid PCR testing platform for the detection of infectious disease pathogens, including SARS-CoV-2 and other infectious agents. The system is designed for use by healthcare providers and medical laboratories to enable rapid, on-site molecular diagnostics and faster clinical decision-making.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SpinDiag is a German diagnostics company specializing in infectious disease testing. Based on the available information, the company has developed a rapid PCR testing platform for detecting pathogens such as SARS-CoV-2 and other infectious agents. The company received a €15 million loan from the European Investment Bank (EIB) to further develop its testing platform and support market expansion across Europe.

Product and service1 record
1Rapid PCR Testing Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Hologic
TypeBroad incumbent
Description

Hologic's Panther and Aptima systems anchor molecular diagnostics in central laboratories and near-patient settings. While not a POCT cartridge platform, it competes for the same hospital infectious-disease testing budget.

2bioMérieux
TypeDirect peer
Description

bioMérieux's BioFire FilmArray panels are widely used syndromic molecular PCR systems in hospitals. They share SpinDiag's model of cartridge-based multiplex PCR testing for infectious diseases, with a much larger installed base.

3Roche Diagnostics
TypeDirect peer
Description

Roche's cobas Liat is a compact, rapid PCR point-of-care system delivering results in 20 minutes for pathogens including SARS-CoV-2, Strep A, and influenza. It competes head-to-head with SpinDiag for hospital and near-patient testing slots.

4Cepheid (Danaher)
TypeDirect peer
Description

Cepheid's GeneXpert system is the dominant molecular point-of-care PCR platform globally, used in hospitals and laboratories for infectious disease testing. It is the most direct commercial and technological comparable to SpinDiag's rapid PCR POCT platform.

5T2 Biosystems
TypeEmerging player
Description

T2 Biosystems offers rapid molecular diagnostic systems (T2 Magnetic Resonance-based) for sepsis and infectious disease. It is an emerging point-of-care molecular diagnostics peer with a comparable scale and stage profile.

6QIAGEN
TypeBroad incumbent
Description

QIAGEN is a broad molecular diagnostics and sample-preparation provider with PCR reagent kits and QIAstat-Dx, a cartridge-based molecular POCT system. It is an incumbent in SpinDiag's overlapping workflow.

7Bosch Healthcare Solutions
TypeDirect peer
Description

Bosch's Vivalytic is a German-developed compact PCR point-of-care platform targeting European hospitals and laboratories with rapid infectious disease testing. It is one of the closest geographic and technical competitors to SpinDiag.

8Mesa Labs
TypeEmerging player
Description

Mesa Labs offers rapid microbial and diagnostic test systems used in healthcare and laboratory settings. While more focused on sterility and contamination testing, it competes in the same broad rapid-testing purchasing channels as SpinDiag.

9Abbott
TypeDirect peer
Description

Abbott's ID NOW platform is an isothermal molecular rapid point-of-care system widely deployed for influenza, Strep A, and SARS-CoV-2 testing. It competes with SpinDiag on speed, footprint, and clinical setting.

10OpGen (Curetis)
TypeEmerging player
Description

Curetis (acquired by OpGen) developed the Unyvero molecular cartridge platform for severe infectious disease diagnostics. It is a comparable European-headquartered molecular cartridge company with a similar scaling trajectory.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpinDiag

Molecular Diagnosticsspindiag.de

SpinDiag (Spindiag GmbH) is a Freiburg, Germany-based diagnostics startup that develops a rapid, automated point-of-care PCR testing platform for detecting infectious disease pathogens such as SARS-CoV-2, serving healthcare providers and medical laboratories across Europe.

What SpinDiag does

SpinDiag GmbH is a German diagnostics company headquartered in Freiburg that develops a rapid, automated, point-of-care PCR testing platform for infectious disease detection, with publicly disclosed applications including SARS-CoV-2 and other pathogens. The company's core product is a compact, easy-to-use PCR system designed to deliver laboratory-grade molecular diagnostic results outside of centralized lab settings, with speed (performance_speed) cited as the primary technical differentiator. The platform is positioned for use by healthcare providers and medical laboratories — a B2B customer segment characterized by hospital systems, clinical labs, and point-of-care clinical sites requiring rapid, accurate infectious disease diagnosis. Revenue model, pricing, and distribution channels are not publicly disclosed; the company is privately held and was founded in 2016.

SpinDiag has raised approximately $42 million across five funding rounds between 2017 and 2022, including a €15 million debt facility from the European Investment Bank in October 2022 earmarked for R&D, production scale-up, and geographic expansion across European markets. The leadership team is founder-heavy, with multiple technical co-founders (CSO, CTO, CPO, and a scientific co-founder) alongside dedicated CEO, COO, and CFO functions, reflecting an organization built for both deep product development and commercial scaling. Operating geographies are centered on Germany with broader European expansion signaled via EIB-financed commercialization.

Significant uncertainty is introduced by the fact that SpinDiag's primary web domain (spindiag.de) appears to have been repurposed for unrelated online casino and gambling content, an indicator of operational disruption, domain expiry, or business discontinuation that is not otherwise explained in the available data and which materially affects any assessment of current commercial status.

SpinDiag firmographics

Firmographics
Name
SpinDiag
Legal name
Spindiag GmbH
Website
https://spindiag.de
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
SpinDiag (Spindiag GmbH) is a Freiburg, Germany-based diagnostics startup that develops a rapid, automated point-of-care PCR testing platform for detecting infectious disease pathogens such as SARS-CoV-2, serving healthcare providers and medical laboratories across Europe.
Ownership category
akta.pro rank

SpinDiag industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

  • PCR diagnostic testing
  • Infectious disease detection
  • Point-of-care diagnostics
  • Molecular diagnostics platform
  • Rapid pathogen testing

Where SpinDiag is headquartered

Location

Headquarters

HQ city
Freiburg
HQ country
Germany
HQ region
Europe

Markets served

SpinDiag business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations

SpinDiag product offering

Product offering

Core offering

SpinDiag (Spindiag GmbH) develops an easy-to-use, compact, and automated point-of-care rapid PCR testing platform for the detection of infectious disease pathogens, including SARS-CoV-2 and other infectious agents. The system is designed for use by healthcare providers and medical laboratories to enable rapid, on-site molecular diagnostics and faster clinical decision-making.

Product overview

SpinDiag is a German diagnostics company specializing in infectious disease testing. Based on the available information, the company has developed a rapid PCR testing platform for detecting pathogens such as SARS-CoV-2 and other infectious agents. The company received a €15 million loan from the European Investment Bank (EIB) to further develop its testing platform and support market expansion across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rapid PCR Testing Platform

Companies that use SpinDiag

Customer profile

Segments1 record

Ideal customer profiles1 record

SpinDiag technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SpinDiag partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

SpinDiag competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic's Panther and Aptima systems anchor molecular diagnostics in central laboratories and near-patient settings. While not a POCT cartridge platform, it competes for the same hospital infectious-disease testing budget.
  • QIAGEN: QIAGEN is a broad molecular diagnostics and sample-preparation provider with PCR reagent kits and QIAstat-Dx, a cartridge-based molecular POCT system. It is an incumbent in SpinDiag's overlapping workflow.

Direct peers

  • bioMérieux: bioMérieux's BioFire FilmArray panels are widely used syndromic molecular PCR systems in hospitals. They share SpinDiag's model of cartridge-based multiplex PCR testing for infectious diseases, with a much larger installed base.
  • Roche Diagnostics: Roche's cobas Liat is a compact, rapid PCR point-of-care system delivering results in 20 minutes for pathogens including SARS-CoV-2, Strep A, and influenza. It competes head-to-head with SpinDiag for hospital and near-patient testing slots.
  • Cepheid (Danaher): Cepheid's GeneXpert system is the dominant molecular point-of-care PCR platform globally, used in hospitals and laboratories for infectious disease testing. It is the most direct commercial and technological comparable to SpinDiag's rapid PCR POCT platform.
  • Bosch Healthcare Solutions: Bosch's Vivalytic is a German-developed compact PCR point-of-care platform targeting European hospitals and laboratories with rapid infectious disease testing. It is one of the closest geographic and technical competitors to SpinDiag.
  • Abbott: Abbott's ID NOW platform is an isothermal molecular rapid point-of-care system widely deployed for influenza, Strep A, and SARS-CoV-2 testing. It competes with SpinDiag on speed, footprint, and clinical setting.

Emerging players

  • T2 Biosystems: T2 Biosystems offers rapid molecular diagnostic systems (T2 Magnetic Resonance-based) for sepsis and infectious disease. It is an emerging point-of-care molecular diagnostics peer with a comparable scale and stage profile.
  • Mesa Labs: Mesa Labs offers rapid microbial and diagnostic test systems used in healthcare and laboratory settings. While more focused on sterility and contamination testing, it competes in the same broad rapid-testing purchasing channels as SpinDiag.
  • OpGen (Curetis): Curetis (acquired by OpGen) developed the Unyvero molecular cartridge platform for severe infectious disease diagnostics. It is a comparable European-headquartered molecular cartridge company with a similar scaling trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

SpinDiag social profiles

Digital presence

SpinDiag financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpinDiag leadership team

Management profile

Number of profiles

Profiles8 records

SpinDiag funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpinDiag M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpinDiag

What does SpinDiag do?

SpinDiag (Spindiag GmbH) develops an easy-to-use, compact, and automated point-of-care rapid PCR testing platform for the detection of infectious disease pathogens, including SARS-CoV-2 and other infectious agents. The system is designed for use by healthcare providers and medical laboratories to enable rapid, on-site molecular diagnostics and faster clinical decision-making.

Is SpinDiag a public or private company?

SpinDiag is a private company. It is classified as venture growth investor backed and is currently operating.

When was SpinDiag founded?

SpinDiag was founded in 2016. It employs 51 to 100 people.

Where is SpinDiag based?

SpinDiag is headquartered in Freiburg, Germany, in the Europe region.

Who are SpinDiag's main competitors?

Broad incumbents on record are Hologic and QIAGEN. Direct peers are bioMérieux, Roche Diagnostics, Cepheid (Danaher), Bosch Healthcare Solutions and Abbott. Emerging players are T2 Biosystems, Mesa Labs and OpGen (Curetis).

Does SpinDiag have an API?

No public API is recorded for SpinDiag.

What industry is SpinDiag in?

SpinDiag's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon CanalsGermany-based Spindiag bags €15M EIB loan for its rapid PCR testing platformSpindiag, a Germany-based in vitro diagnostics startup, secured a €15M loan from the European Investment Bank (EIB) to further develop and commercialize its rapid PCR testing platform. The funding, facilitated by the EU's Infectious Diseases Finance Facility, will support the expansion of the company's Rhonda system capabilities and its market entry into other European countries.EibGermany: EIB provides finance of €15 million for Spindiag’s novel PCR diagnostics systemThe European Investment Bank (EIB) has provided a €15 million loan to Spindiag GmbH to support the further development and commercialisation of its rapid PCR diagnostic testing platform. This funding, backed by the EU's Infectious Diseases Finance Facility, will be used for research, scaling production, and expanding Spindiag's operations into other European markets from its base in Germany.PR NewswireSpindiag nomme Winston Griffin au poste de directeur financier en vue d'appuyer sa stratégie financière mondiale et d'expansion du marchéSpindiag GmbH appointed Winston Griffin as its Chief Financial Officer to support its global financial strategy and market expansion. Griffin joins from Procter & Gamble, bringing extensive international finance experience after four years of funding rounds totaling 24.9 million euros for the company's diagnostic systems.PR NewswireSpindiag Appoints Winston Griffin as Chief Financial Officer to Support its Global Finance and Market Expansion StrategySpindiag GmbH appointed Winston Griffin, formerly of Procter & Gamble, as its new Chief Financial Officer effective August 3, 2020. Griffin brings over 30 years of international finance experience and will lead the company's finance organization as it prepares for the market launch of its Rhonda point-of-care rapid testing system, including a planned SARS-CoV-2 rapid test. The German in vitro diagnostics company has secured EUR 24.9 million in total funding across four financing rounds and received EUR 6 million in state funding from Baden-Wuerttemberg for COVID-19 test development.PR NewswireSpindiag ernennt Winston Griffin zum Finanzvorstand zur Entwicklung der globalen Unternehmens- und FinanzstrategieSpindiag GmbH, an in-vitro diagnostics company based in Freiburg im Breisgau, Germany, appointed Winston Griffin as Chief Financial Officer, effective August 3, 2020. Griffin joined from Procter & Gamble, where he most recently served as Vice President Europe leading Finance and Accounting for the Beauty Care division across EU and Eastern European markets, bringing over 30 years of international finance experience. In his new role, Griffin will be responsible for developing and implementing Spindiag's long-term financial and market expansion strategy, including the planned market launch of the company's Rhonda Point-of-Care rapid test system for infectious disease diagnostics including SARS-CoV-2.FinSMEsSpinDiag Closes €3M Series A Funding RoundSpinDiag, a Freiburg-based healthtech startup, closed a €3M Series A funding round. The funds will support clinical validation in Europe next year. The company's point-of-care screening system tests high-risk patients for drug resistance.